NovMetaPharma is a leading pharmaceutical company specializing in the development of innovative drugs with differentiated mechanisms for metabolic diseases. With our unique technological capabilities and efficient development system, we are poised to lead the global market for metabolic disease treatments. Our focus is on the development of safe and effective therapies for metabolic diseases, addressing the challenges faced by numerous patients and their families.

The number of people worldwide suffering from metabolic diseases, which have characteristics of chronic conditions, has already exceeded one-fifth of the global population and continues to grow each year. As the demand for new drugs that can be safely and confidently used for an extended period of time rises, NovMetaPharma has made the commitment to develop such treatments. We conduct clinical trials not only in Korea but also in the United States, Australia, and other countries, relentlessly pursuing the path of new drug development.

Our journey in developing new drugs over the past decade reflects not only our own dreams but also the aspirations of countless patients and their families struggling with metabolic diseases. Therefore, every employee at NovMetaPharma approaches each step and decision with unwavering focus and a deep sense of responsibility. We promise to do our best and never stop moving forward, fueled by the support and expectations of everyone who believes in us until the day when the long-held dreams of patients and their families become a tangible reality